Literature DB >> 10693959

Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain.

Y Ye1, K Jackson, J M O'Donnell.   

Abstract

In a previous study, an up-regulation of rolipram-sensitive, low-Km, cyclic AMP phosphodiesterase (PDE4) subtype PDE4A in rat cerebral cortex following repeated treatment of desipramine was observed. To determine whether this effect is shared by antidepressants from different pharmacological classes, PDE4A expression was examined using immunoblot analyses following repeated treatment with the norepinephrine re-uptake inhibitor desipramine, the monoamine oxidase inhibitor phenelzine, the atypical antidepressant trazodone, and the serotonin reuptake inhibitor fluoxetine. Desipramine, phenelzine, and fluoxetine all increased the intensities of the PDE4A bands in hippocampal preparations; trazodone did not. In preparations of cerebral cortex, the intensities of the PDE4A bands were increased following desipramine treatment, not changed following phenelzine or fluoxetine treatment, and decreased following trazodone treatment. It appears that repeated treatment with antidepressant drugs from different pharmacological classes produces similar effects on the expressions of PDE4A variants in hippocampus. This effect is not correlated with the changes in beta-adrenergic receptor densities, suggesting these antidepressants may at some point alter intracellular signal transduction pathways in a similar manner.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693959     DOI: 10.1046/j.1471-4159.2000.741257.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

3.  Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Authors:  John R Cashman; Troy Voelker; Han-Ting Zhang; James M O'Donnell
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

4.  Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

Authors:  Lan Xiao; James P O'Callaghan; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2011-05-12       Impact factor: 4.030

5.  Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B).

Authors:  Han-Ting Zhang; Ying Huang; Anbrin Masood; Lisa R Stolinski; Yunfeng Li; Lei Zhang; Daniel Dlaboga; S-L Catherine Jin; Marco Conti; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2007-08-15       Impact factor: 7.853

6.  Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus.

Authors:  David Terburg; Supriya Syal; Lisa A Rosenberger; Sarah Heany; Nicole Phillips; Nigel Gericke; Dan J Stein; Jack van Honk
Journal:  Neuropsychopharmacology       Date:  2013-08-01       Impact factor: 7.853

7.  Sex differences in the genetic architecture of depression.

Authors:  Hee-Ju Kang; Yoomi Park; Ju Han Kim; Jae-Min Kim; Kyung-Hun Yoo; Ki-Tae Kim; Eun-Song Kim; Ju-Wan Kim; Sung-Wan Kim; Il-Seon Shin; Jin-Sang Yoon
Journal:  Sci Rep       Date:  2020-06-18       Impact factor: 4.379

Review 8.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

9.  Candidate genes for antidepressant response to selective serotonin reuptake inhibitors.

Authors:  Francis E Lotrich; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.